Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Baxter 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Baxter 1Q

BioScience business revenues up 2%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxter

1Q Revenues: $3.8 billion (-2%)
 
1Q Earnings: $430 million (-23%)
 
Comments: Sales in the U.S. grew 4% to $1.7 billion, while international sales were $2.1 billion, down 6%. Excluding the impact of foreign currency, Baxter’s sales grew 4% in the quarter. Baxter’s BioScience business generated revenues of $1.4 billion, up 2% driven by immunoglobulin treatments for primary immunodeficiency (PI), hemophilia and inhibitor therapies, and certain biotherapeutics. Medical Products sales were $2.4 billion, down 5%. Excluding foreign currency, sales increased 2%. Results include separation-related costs of $117 million for the planned separation of Baxter’s biopharmaceutical and medical products businesses and charges of $18 million related to the integration of Gambro.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters